NCT00261495 - A Study of the Effectiveness and Safety of Sustained-release Hydromorphone (a Strong Opioid) in Patients With Chronic Noncancer Pain. | Biotech Hunter

Enrollment

504

Participants

Timeline

Start Date

March 31, 2006

Primary Completion Date

April 30, 2008

Study Completion Date

April 30, 2008

Conditions

Pain

Interventions

DRUG

OROS hydromorphone HCl

8 to 32 mg once daily for 52 weeks (flexible dosing)

DRUG

Oxycodone

10, 20, or 40 mg twice a day for 52 weeks (flexible dosing)

Trial Locations (52)

Unknown

Brno

Pilsen

Prague

Copenhagen

Esbjerg

Nyborg

Svendborg

Vejle

Amiens

Bois-Guillaume

Lille

Paris

Berlin

Drensteinfurt

Dresden

Duderstadt

Frankfurt

Giessen

Göppingen

Hamburg

Herne

Jena

Kiel

Kÿln

Ludwigshafen

Mannheim

Nuremberg

Regensburg

Rodgau

Wiesbaden

Bodø

Lørenskog

Oslo

Gdansk

Krakow

Lublin

Warsaw

Wroclaw

Banská Bystrica

Bratislava

Martin

Prešov

Ljubljana

Maribor

Slovenj Gradec

Gothenburg

Jönköping

Kristianstad

Linköping

Aarau

Basel

Lausanne

All Listed Sponsors

lead

Janssen Pharmaceutica N.V., Belgium

INDUSTRY